Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer.
Journal:
The Journal of thoracic and cardiovascular surgery
PMID:
30718052
Abstract
OBJECTIVE: We conducted a phase I trial of neoadjuvant nivolumab, a monoclonal antibody to the programmed cell death protein 1 checkpoint receptor, in patients with resectable non-small cell lung cancer. We analyzed perioperative outcomes to assess the safety of this strategy.